Test Background
Up to 10% of the population has difficulty maintaining muscle mass due to variant genes. SNP Therapeutics has developed a genetic test and algorithm that can identify a subset of the population who are unable to maintain muscle mass due to SNPs preventing the proper metabolism of one carbon nutrients.
-
![Gene Guided Nutri Icon]()
Muscle Wasting Market Opportunity
Thirty two million americans suffer with muscle wasting. The market is forecast to grow to nearly $4Bn by 2024.
-
![Gene Guided Nutri Icon]()
Potential Markets
SNP Therapeutics is well positioned to participate in this growing market with potential products focusing in the Sports Nutrition and Aging Consumer Health segments.
-
![Gene Guided Nutri Icon]()
Clinical Research
SNP Therapeutics is seeking partnerships to develop clinical studies focused on identifying and treating athletes, the elderly, as well as military patient populations.
